[go: up one dir, main page]

GT200600496A - SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA. - Google Patents

SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA.

Info

Publication number
GT200600496A
GT200600496A GT200600496A GT200600496A GT200600496A GT 200600496 A GT200600496 A GT 200600496A GT 200600496 A GT200600496 A GT 200600496A GT 200600496 A GT200600496 A GT 200600496A GT 200600496 A GT200600496 A GT 200600496A
Authority
GT
Guatemala
Prior art keywords
profarms
piirimidin
isopropil
carbonil
phenil
Prior art date
Application number
GT200600496A
Other languages
Spanish (es)
Inventor
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Ravi Mysore Shanker
Franzanne Vreeland
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GT200600496A publication Critical patent/GT200600496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA 1, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE, PROFÁRMACO O HIDRATOS DE LOS MISMOS. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOISICONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS DE FÓRMULA 1, Y A MÉTODOS PARA TRATAR TRASTORONOS HIPERPROLIFERATIVOS EN UN MAMÍFERO POR MEDIO DE LA ADMINISTRACIÓN DE LOS COMPUESTOS DE FÓRMULA 1. T2006THE PRESENT INVENTION REFERS TO COMPOUNDS OF FORMULA 1, OR A PHARMACEUTICALLY ACCEPTABLE, PROPHARM OR HYDRAPHY SALT OF THE SAME. THE INVENTION ALSO REFERS TO PHARMACEUTICAL COMPOUNDS CONTAINING FORMULA 1 COMPOUNDS, AND METHODS TO TREAT HYPERPROLIFERATIVE DISORDERS IN A MAMMER THROUGH THE ADMINISTRATION OF FORMULA COMPOUNDS 1.

GT200600496A 2005-12-09 2006-12-07 SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA. GT200600496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
GT200600496A true GT200600496A (en) 2007-07-17

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600496A GT200600496A (en) 2005-12-09 2006-12-07 SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA.

Country Status (8)

Country Link
AR (1) AR058293A1 (en)
DO (1) DOP2006000271A (en)
GT (1) GT200600496A (en)
NL (1) NL2000337A1 (en)
PE (1) PE20071037A1 (en)
TW (1) TW200733965A (en)
UY (1) UY29991A1 (en)
WO (1) WO2007066189A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068916A1 (en) * 2007-10-19 2009-12-16 Abbott Gmbh & Co Kg SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND
JP2011500649A (en) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Solid dispersion products of N-arylureas
DK2358720T3 (en) * 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
CN102892768A (en) 2009-12-30 2013-01-23 艾科尔公司 Substituted pyrrolo-aminopyrimidine compounds
ES2676209T3 (en) * 2010-06-23 2018-07-17 Metabolex Inc. Compositions of 5-ethyl-2- {4- [4- (4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
CN107652289B (en) 2012-06-13 2020-07-21 因塞特控股公司 Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
RU2015115631A (en) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния MODULATION IRE1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (en) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
CN107722012B (en) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (en) 2018-05-04 2021-02-02 Incyte Corporation salts of a fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (en) 2019-12-04 2025-08-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
CN115151539A (en) 2019-12-04 2022-10-04 因赛特公司 Derivatives of FGFR Inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2025015449A (en) * 2023-07-18 2025-01-30 信越化学工業株式会社 Composition for solid dispersion, solid dispersion, and method of manufacturing solid dispersion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (en) * 1997-08-11 2007-08-07 Pfizer Prod Inc Solid pharmaceutical dispersions with enhanced bioavailability
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
UY29991A1 (en) 2007-07-31
NL2000337A1 (en) 2007-06-12
DOP2006000271A (en) 2007-08-15
TW200733965A (en) 2007-09-16
AR058293A1 (en) 2008-01-30
PE20071037A1 (en) 2007-11-19
WO2007066189A3 (en) 2008-08-14
WO2007066189A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
GT200600496A (en) SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA.
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
ECSP034773A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
CY1115058T1 (en) 1,2,3-TRIZOLIS PRODUCT FOR USE AS STEATOILO-COA SUSPENSIONS
AR028810A1 (en) DERIVATIVES OF ARILPIPERAZINIL-CICLOHEXIL INDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPRESSION
ECSP055853A (en) NEW DERIVATIVES OF HETEROCICLIC FLUOROGLYCOSIDS, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS, AND THE USE OF THE SAME
PA8595901A1 (en) "N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND THEIR EMPLOYMENT AS MEDICATIONS
UY30460A1 (en) THERAPEUTIC COMPOUNDS
NO20075111L (en) Pharmaceutical composition
BRPI0510770A (en) derivatives of pyrazol fluoroglycosides, medicines containing these compounds and their use
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
CR10027A (en) NEW DERIVATIVES OF FUSIONATED PIRROL
AR080491A1 (en) ORAL FORMULATIONS AND LIPOFILIC SALTS OF METHYLNTREXONE
ECSP088296A (en) THERAPEUTIC COMPOUNDS
CO5580767A2 (en) INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE
UY27374A1 (en) USE OF NK-1 RECEIVER ANTAGONISTS FOR THE TREATMENT OF BRAIN, SPINAL OR NEURONAL INJURIES
ECSP10010052A (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CL2008000750A1 (en) METHOD FOR THE ADMINISTRATION OF A WEEKLY DOSE OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) 3-METHYL-2,4 DIOXO-3,4 DIHYDRO-2H-PIRIMIDIN-1-IL METIL] -4 FLUORO-BENZONITRILE; PHARMACEUTICAL COMPOSITION OF AN INDIVIDUAL DOSAGE FORM OF SUCH COMPOUND; AND HIS
GT200500309A (en) DERIVATIVES OF SULFONILBENCILIMIDAZOL
WO2008074833A3 (en) Compounds
UY27018A1 (en) PIRIMIDINE DERIVATIVES
BRPI0410044A (en) dosage form containing pantoprazole as active ingredient
AR064543A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS